RecruitingPhase 1NCT06792734

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Sponsor

Bantam Pharmaceuticals

Enrollment

24 participants

Start Date

Feb 14, 2025

Study Type

INTERVENTIONAL

Conditions

Lymphoma, B-Cell

Summary

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)? Participants will: Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase study tests a new drug called BTM-3566 in people with mature B-cell lymphomas — a group of blood cancers — that have come back or stopped responding to previous treatments. The study aims to find the right dose and assess safety. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of relapsed or refractory B-cell lymphoma - Your lymphoma can be measured on scans - Your overall health status is adequate (ECOG 0–2) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have primary CNS (brain) lymphoma - You have ongoing significant side effects from prior cancer treatment - You have received other cancer therapy within 28 days before study enrollment - You have an active second cancer at another site Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.